Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3746 participants.

Also called NCT03234114

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,746 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03234114
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03234114. Randomized; no masking; primary purpose treatment. Start 2018-02-03 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
Condition
Acute Coronary Syndrome (ACS)
Condition
Non-valvular Atrial Fibrillation (NVAF)
Intervention (Drug)
Triple antithrombotic therapy
Intervention (Drug)
Dual antithrombotc therapy-1
Intervention (Drug)
Dual antithrombotc therapy-2
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct03234114
Content hash
dca39f095029e7752c52323cf76d18ba909806bc607681c9f6246e8330c50154